Array BioPharma (NASDAQ:ARRY) issued its quarterly earnings data on Thursday. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.05, American Banking News reports. The company had revenue of $14.20 million for the quarter, compared to the consensus estimate of $11.20 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was down 10.1% on a year-over-year basis.
Array BioPharma (NASDAQ:ARRY) remained flat at $5.24 during during mid-day trading trading on Thursday. 352,484 shares of the company’s stock traded hands. Array BioPharma has a 52 week low of $3.25 and a 52 week high of $7.10. The stock has a 50-day moving average of $5.91 and a 200-day moving average of $5.7. The company’s market cap is $613.2 million.
ARRY has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their price target on shares of Array BioPharma from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Array BioPharma from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $7.67.
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.